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ABSTRACT 1 
The filamentous fungus Aspergillus fumigatus is responsible for a lethal disease called invasive 2 
aspergillosis that affects immunocompromised patients. This disease, like other human fungal 3 
diseases, is generally treated by compounds targeting the primary fungal cell membrane sterol. 4 
Recently, glucan synthesis inhibitors were added to the limited antifungal arsenal and 5 
encouraged the search for novel targets in cell wall biosynthesis. Although it is a major 6 
component of A. fumigatus cell wall and extracellular matrix, the biosynthesis and role of 7 
galactomannan are currently unknown. By a targeted gene deletion approach, we demonstrate 8 
that UDP-galactopyranose mutase, a key enzyme of galactofuranose metabolism, controls the 9 
biosynthesis of galactomannan and galactofuranose containing glycoconjugates. The glfA 10 
deletion mutant generated in this study is devoid of galactofuranose and displays attenuated 11 
virulence in a low dose mouse model of invasive aspergillosis that likely reflects the impaired 12 
growth of the mutant at mammalian body temperature. Furthermore, the absence of 13 
galactofuranose results in a thinner cell wall that correlates with an increased susceptibility to 14 
several antifungal agents. The UDP-galactopyranose mutase appears thus as an appealing adjunct 15 
therapeutic target in combination with other drugs against A. fumigatus. Its absence from 16 
mammalian cells offers indeed a considerable advantage to achieve therapeutic selectivity. 17 
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INTRODUCTION 1 
The filamentous fungus Aspergillus fumigatus is the primary cause of invasive aspergillosis, an 2 
often fatal condition affecting people with a weakened immune system. Along with the 3 
immunocompromised population, the incidence of invasive aspergillosis is constantly growing 4 
but therapy remains problematic. The sterol binding polyene amphotericin B and ergosterol 5 
biosynthesis inhibitor itraconazole have long been the drugs of choice for treatment of this 6 
infection. But because of their higher efficacy and lower toxicity, new triazoles such as 7 
voriconazole or posaconazole are supplanting these drugs  (28,33). Additionally, a novel class of 8 
antifungal agents called the echinocandins provides further options for treatment. These 9 
compounds inhibit the synthesis of β1,3-glucan, a major cell wall component with resultant 10 
osmotic instability and lysis (12). Their minimal toxicity and synergistic activity with 11 
voriconazole and amphotericin B make them particularly attractive for combination therapy 12 
although clinical validation is still awaited (35,33). Despite these advances in therapy, invasive 13 
aspergillosis is often associated with significant morbidity and mortality emphasizing the need 14 
for novel therapeutic strategies based on the fundamental knowledge of A. fumigatus 15 
pathogenesis.  16 
The development of echinocandins illustrates the viability of targeting enzymes involved in cell 17 
wall biosynthesis and encourages the development of chitin synthesis inhibitors. Like glucan and 18 
chitin, galactomannan is an abundant component of A. fumigatus cell wall (4). This 19 
polysaccharide composed of a linear mannan core branched with short β1,5-linked 20 
galactofuranose (Galf) chains (22) is covalently bound to the cell wall β1,3-glucan, anchored to 21 
the lipid membrane by a glycosylphosphatidylinositol (GPI), or released in the environment 22 
during tissue invasion or growth in culture (3,9,14). Besides being an abundant component of the 23 
extracellular matrix, secreted galactomannans are used for serological diagnostic of invasive 24 
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aspergillosis (1). The monosaccharide Galf has also been reported in the N- and O-glycans of 1 
some glycoproteins as well as the glycosphingolipids of A. fumigatus (47,29,23,41) and 2 
represents thus an important constituent of this fungus cell wall. Galf is otherwise infrequent in 3 
natural compounds but prevalent in pathogens. Moreover since it is absent from higher 4 
eukaryotes and involved in the survival or virulence of various bacteria, the enzymes involved in 5 
the biosynthesis of Galf are considered as attractive drug targets (32,34).  6 
Our understanding of Galf metabolism in eukaryotes is limited. Galf is most likely incorporated 7 
into cell surface components by specific galactofuranosyltransferases using UDP-Galf
 
as donor. 8 
The work of Trejo and colleagues in early 1970s already suggested the existence of an enzyme 9 
converting UDP-galactopyranose into UDP-galactofuranose involved in the biosynthesis of 10 
fungal cell wall (48). This enzyme named UDP-galactopyranose mutase (UGM) and encoded by 11 
the glf gene was first described in bacteria (17,50,30) and lately in several eukaryotic pathogens 12 
including A. fumigatus (2,5). UGM is to date the only characterised enzyme involved in the 13 
biosynthesis of galactofuranose containing molecules in eukaryotes whereas several 14 
galactofuranosyltransferases have been described in bacteria (15,19,51,27). The identification of 15 
this enzyme, highly conserved amongst lower eukaryotes and present in many fungi, enables 16 
studies on the biological role of galactofuranose in these organisms. The present report highlights 17 
the role of galactofuranose in Aspergillus fumigatus growth and virulence. 18 
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MATERIAL AND METHODS 1 
Strains, media and growth conditions. Aspergillus fumigatus clinical isolate D141 (38) was 2 
used as wild type strain in this study. All strains were grown at 37 °C on Aspergillus minimal 3 
medium (AMM) containing 1 % D-glucose as carbon source and 70 mM NaNO3 as nitrogen 4 
source (36) unless otherwise stated. Phleomycin or 5-fluoro-2’-deoxyuridine (FUDR) were 5 
added for selection purposes at 30 µg/mL and 100 µM respectively.  6 
 7 
Generation of A. fumigatus mutant strains. The 5’ and 3’ flanking regions (1.5 and 2 kb 8 
respectively) of A. fumigatus glfA coding sequence were amplified from genomic DNA by PCR 9 
with primers PS12/PS1 and PS3/PS4 (Table 1) respectively and cloned into the pBluescript II 10 
SK(-) vector (Stratagene) using the restriction sites SacII/NotI and EcoRV/ClaI. A SpeI/NotI 11 
fragment released from pSK269 containing the phleo/tk blaster (18) was then inserted between 12 
the two fragments to obtain the disruption plasmid p∆glfA. For reconstitution of the glfA gene 13 
locus, the plasmid pglfA* was constructed as follows. The phleo/tk blaster of p∆glfA was first 14 
replaced with the original A. fumigatus glfA gene by homologous recombination in E. coli strain 15 
YZ2000 (Gene Bridges, Leimen, Germany). A single point mutation was introduced by site-16 
directed mutagenesis. Briefly, non-methylated plasmid DNA was generated from a methylated 17 
parent plasmid by Phusion DNA-Polymerase (NEB) using complementary primers that both 18 
carried the desired mutation (PS23s/PS23r, Table 1). Prior to transformation the parental, 19 
methylated DNA strand was specifically cleaved by DpnI to selectively obtain transformants that 20 
harbored the mutated plasmid. Thus, codon 130 of glfA coding sequence (GenBank Accession 21 
number AJ871145) was changed from CTT to CTC which generated a new XhoI restriction site. 22 
Since gene reconstitution by homologous recombination could not be obtained with this 23 
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construct, 5’ and 3’ flanking regions were extended to 5 kb by replacement with re-cloned PCR 1 
fragments (primer pairs PS28/PS1 and PS3/PS31) to obtain the final pglfA* construct.  2 
The p∆glfA and pglfA* plasmids were linearised (KpnI/SacII) before polyethylene glycol-3 
mediated fusion of protoplasts as described in (37). Transformants were grown on AMM plates 4 
containing 1.2 M sorbitol as osmotic stabiliser under appropriate selection conditions and singled 5 
out twice before further analysis. Accurate gene deletion and reconstitution were confirmed by 6 
southern hybridisation. Southern probes were amplified from genomic DNA using primer pairs 7 
PS66A/PS67A, PS68A/PS69A and PS20/PS21. All primer sequences are provided in Table 1. 8 
 9 
Western Blots. Cell wall glycoproteins and soluble polysaccharides were extracted from 30 mg 10 
ground A. fumigatus mycelium by incubation in 1 mL sample buffer (15 % glycerol, 100 mM 11 
Tris/HCl pH 6.8, 1.5 % SDS, 0.25 % β-mercaptoethanol, 0.025 % bromophenol blue) for 12 min 12 
at 95 °C. 20 µl of the supernatant were separated on a 10 % SDS-polyacrylamide gel and 13 
transferred to nitrocellulose membranes. The monoclonal antibody EB-A2 (42) conjugated to 14 
horseradish peroxidase (HRP) from the Platelia Aspergillus Test (Bio-Rad, Hercules, CA, USA) 15 
or HRP-coupled lectin Concanavalin A (ConA, Sigma-Aldrich) were used in a 1:50 dilution or at 16 
0.2 µg/mL respectively. HRP activity was visualised by an enhanced chemiluminescence system 17 
(Pierce, Rockford, IL, USA). 18 
 19 
N-glycan analysis. N-glycans of secreted glycoproteins in the supernatant of an A. fumigatus 20 
liquid culture were analyzed after Peptide N-Glycosidase F (PNGase F) mediated release and 8-21 
amino-1,3,6-pyrenetrisulfonic acid (APTS) labeling by capillary electrophoresis as recently 22 
described (20). Separation was carried out on a 4-capillary electrophoresis DNA Sequencer 23 
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(3130 Genetic Analyzer, Applied Biosystems, Foster City, CA, USA). Oligomaltose and bovine 1 
RNAse B N-glycans (Prozyme, San Leandro, CA, USA) served as reference oligosaccharides. 2 
 3 
Purification and analyis of glycosylinositolphosphoceramides (GIPCs). Mycelia (0.5 g) 4 
ground in liquid nitrogen with a mortar and pestle were disrupted by sonication in 6 mL of 5 
CHCl3/MeOH 1:1. After addition of 3 mL CHCl3 (to obtain a CHCl3/MeOH ratio of 2:1), GIPCs 6 
were extracted at room temperature for at least 15 min on a rotating shaker. 3 mL MeOH were 7 
then added to lower the density and the mixture centrifuged for 10 min at 2000 g to remove 8 
insoluble material. Chloroform and H2O were then added to the supernatant to obtain a biphasic 9 
system with an 8/4/3 ratio of CHCl3/MeOH/H2O. After centrifugation for 10 min at 2000 g, 10 
GIPCs contained in the upper phase were collected and applied to a C18/SepPak cartridge 11 
(Waters, Eschborn, Germany) pre-equilibrated with 5 mL CHCl3/MeOH/H2O 3/48/47. After 12 
washing of the column with 20 mL CHCl3/MeOH/H2O 3/48/47, glycolipids were eluted with 5 13 
mL methanol and dried under a stream of nitrogen. High performance thin layer chromatography 14 
and immunostaining with the monoclonal antibody MEST-1 were carried out as previously 15 
described (47). 16 
  17 
Growth assay. For radial growth measurement, a 10 µl drop containing 10,000 A. fumigatus 18 
conidia was placed in the centre of an agar plate containing either minimal (AMM) or complete 19 
medium (potato dextrose agar, Becton Dickinson Difco, Heidelberg, Germany). Plates were 20 
incubated at various temperatures and colony diameters were measured twice daily.  21 
 22 
Antifungal susceptibility testing. The reference broth microdilution test was applied for A. 23 
fumigatus antifungal susceptibility testing (21). Each antifungal stock was diluted in 200 µl 24 
ACC
EPT
ED
 at UNIVERSITEIT G
ENT/UZG
ENT on June 18, 2008 
e
c.a
sm
.o
rg
D
ow
nloaded from
 
  8 
double-strength RPMI 2%G (RPMI 1640 liquid medium buffered with 165 mM 4-1 
Morpholinepropanesulfonic acid (MOPS) to pH 7.0 and supplemented with 2 % glucose) to 2 
obtain the highest concentration to be tested. Nine serial 1:2 dilutions in double-strength RPMI 3 
2%G were made and to each dilution an equal volume (100 µl) of an A. fumigatus spore solution 4 
(2.5·105/mL in water) was added. Microtitre plates were incubated at 35 °C and fungal growth in 5 
each well was read out visually after three days and compared to control wells that contained no 6 
antifungal.  7 
 8 
Field emission scanning electron microscopy. For morphological studies and measurements of 9 
the cell wall thickness A. fumigatus wild type and ∆glfA mutant mycelium were fixed in 5 % 10 
formaldehyde and 2 % glutaraldehyde in cacodylate buffer (0.1 M cacodylate, 0.01 M CaCl2, 11 
0.01 M MgCl2, 0.09 M sucrose, pH 6.9) for 1 h on ice. Samples were washed several times with 12 
cacodylate buffer and subsequently with TE-buffer (20 mM Tris/HCl, 1 mM EDTA, pH 6,9) 13 
before dehydration in a graded series of acetone (10, 30, 50, 70, 90, 100 %) on ice for 15 min per 14 
step. Samples in the 100 % acetone step were allowed to reach room temperature before another 15 
change in 100 % acetone. Samples were then subjected to critical-point drying with liquid CO2 16 
(CPD 30, Balzers, Liechtenstein). Dried samples were then mounted onto conductive carbon 17 
adhesive tabs on an aluminium stub and sputter coated with a thin gold film (SCD 40, Balzers 18 
Union, Liechtenstein). For cell wall thickness measurements mycelium was fractured by pressing 19 
another conductive carbon adhesive tab covered stub onto the sample and separating both stubs 20 
immediately thereafter. Fractured hyphae were also made conductive by sputter coating with a 21 
gold film before examination in a field emission scanning electron microscope (Zeiss DSM 982 22 
Gemini) using the Everhart Thornley SE-detector and the inlens SE-detector in a 50:50 ratio at 23 
an acceleration voltage of 5 kV and at calibrated magnifications. 24 
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Mouse infection model. A low-dose mouse infection model of Invasive Aspergillosis for Balb/c 1 
mice which had been established previously (25) was essentially used. Immunosuppressive state 2 
was established by intraperitoneal injections of 100 mg/kg cyclophosphamide (Endoxan, Baxter 3 
Chemicals) on days -4, -1, 0, 2, 5, 8 and 11 and a single subcutaneous dose (200 mg/kg) of a 4 
cortisone acetate suspension (Sigma) on day -1. Groups of 20 mice were infected intranasally 5 
with 20,000 conidia of wt, ∆glfA or glfA* strain on day 0. The control group received PBS only. 6 
Survival was monitored for 13 days after infection and moribund animals were sacrificed. 7 
Coincidence of severely reduced mobility, low body temperature and breathing problems was 8 
defined as moribundity criterion. Statistical analysis of survival data was carried out using the 9 
logrank test implemented in Prism 4 (GraphPad Software, San Diego, CA, USA). For 10 
quantification experiments, groups of three to five animals were killed two, four and six days 11 
after infection and lungs were removed for further analysis.  12 
 13 
Lung histology. 14 
Female Balb/c mice were immunosuppressed and infected as described above. The animals were 15 
killed after 5 days and their lungs removed and fixed in 4 % PBS-buffered paraformaldehyde 16 
over night. Tissue samples were dehydrated through a series of graded alcohols, cleared with 17 
xylene and embedded in paraffin. Tissue sections (5 µm) were stained with either 18 
hematoxylin/eosin or by the Periodic Acid Schiff (PAS) method for visualization of fungal cell 19 
walls. Photomicrographs were taken with an Axiovert 200 M microscope (Zeiss, Germany) at 20 
10x and 20x magnification.  21 
 22 
Preparation of genomic DNA from mouse lungs. Tissue homogenisation was modified 23 
according to (7). Immediately after removal, mouse lungs were transferred to a 2 mL screw-cap 24 
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containing 1.4 mm ceramic beads (Lysing matrix D, Qbiogene, Irvine, CA, USA) and 20 % 1 
glycerol/PBS. Tissue was disrupted using a FastPrep FP120 instrument (Qbiogene) for 3 times 2 
30 seconds at speed 5 with intermediate cooling on ice. The disrupted tissues were further 3 
homogenised with approx. 250 mg acid-washed glass beads (0.45-0.5 mm, Sigma-Aldrich) by 4 
vortexing three times for 30 s with intermediate cooling on ice. The DNeasy Blood & Tissue Kit 5 
(Qiagen, Hilden, Germany) was used to extract genomic DNA from an equivalent of 8 % of the 6 
starting tissue material of this homogenate. DNA was finally recovered in 200 µl elution buffer. 7 
 8 
Quantitative PCR (qPCR). Quantitative PCR was carried out essentially as described 9 
previously (7). Primers for amplification of a 18S rRNA gene (GenBank Accession number 10 
AB008401) fragment specific for A. fumigatus and a hybridisation probe labeled with 11 
carboxyfluorescein (FAM; 5’ end) and carboxytetramethylrhodamine (TAMRA; 3’ end) were 12 
designed using Primer Express software version 3.0 (Applied Biosystems; Table 1). qPCR 13 
reactions were performed in a 7500 Fast Real-Time PCR System instrument (Applied 14 
Biosystems) loaded with MicroAmp optical 96-well plates sealed with Optical Adhesive Cover 15 
(Applied Biosystems). Each qPCR reaction (20 µl) contained 5 µl sample DNA, 250 nM dual-16 
labeled hybridisation probe, 500 nM primers, 250 µg/mL BSA and TaqMan Fast Universal 17 
Master Mix (Applied Biosystems) containing dNTPs, buffer and the fluorescent dye 18 
carboxyrhodamine (ROX) as a passive reference. Real-time PCR data was acquired using 19 
Sequence Detection Software v1.3.1. FAM/ROX fluorescence ratio was recorded at every cycle 20 
and a CT value was assigned to each reaction, defining the cycle number at which the FAM/ROX 21 
signal surpassed an automatically defined threshold. CT values were corrected for differences in 22 
yield of genomic DNA by normalization to DNA concentration of a control sample using the 23 
formula CT,norm = CT,measured + log2([DNA]sample / [DNA]control) (7). Translation of sample CT,norm 24 
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values into rDNA gene copy numbers was done as follows: CT values of serial 1:10 dilutions 1 
containing N = 300 to 300,000 molecules (calculated from Mw and DNA concentration 2 
determined by OD260) of a plasmid bearing the cloned A. fumigatus 18S rDNA gene were plotted 3 
against N to generate a calibration curve which was then used to assign a rDNA copy number to 4 
a given sample CT,norm value. Conidial equivalents were calculated from gene copy numbers by 5 
means of uninfected tissue samples that were spiked with defined numbers of conidia before 6 
tissue homogenisation (7). Samples, controls and standards were analyzed in triplicates. 7 
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RESULTS 1 
Deletion and reconstitution of the glfA gene in A. fumigatus. To begin investigating the role 2 
of Galf in Aspergillus fumigatus biology, we deleted the gene encoding UGM (GenBank locus 3 
tag AJ871145) and named it glfA following the recommendations for gene naming in 4 
Aspergillus. To do this, we generated a deletion plasmid containing the regions flanking the glfA 5 
coding sequence separated by the bifunctional selection cassette phleo/tk that confers both 6 
resistance to phleomycin and sensitivity to 5-fluoro-2’-deoxyuridine (FUDR) (18). This 7 
construct was used to transform protoplasts of A. fumigatus clinical strain D141 which served as 8 
wild type (wt) and phleomycin resistant transformants were analyzed by Southern Blot using 9 
several digoxigenin-labeled probes (Fig. 1). One of the clones that had undergone the desired 10 
gene replacement (Fig. 1) was selected for further analysis and named ∆glfA. 11 
The selected disruptant was further subjected to protoplast transformation with a large DNA 12 
fragment encompassing the glfA coding sequence which contained a single translationally silent 13 
nucleotide exchange that generated an XhoI restriction site. Gene replacement in the 14 
transformants resulted in the reconstitution of the glfA locus (Fig. 1) as detected by FUDR 15 
resistance and proven by Southern Blot analysis for a selected clone named glfA* (Fig. 1B). The 16 
silent mutation introduced in the reconstituted strain allowed differentiating between wild type 17 
and glfA* as demonstrated in figure 1B (top) and thus enabled us to rule out contamination by 18 
the wt strain. The reconstitution of the glfA locus ensures that any phenotype observed in the 19 
∆glfA strain can be reverted and hence be securely attributed to the loss of the glfA gene.  20 
 21 
Galf is absent from the A. fumigatus ∆glfA mutant. To confirm that deletion of glfA indeed 22 
altered the expression of Galf containing glycoconjugates, aqueous mycelial extracts were tested 23 
for reactivity to the Galf-specific monoclonal antibody (mAb) EB-A2. This antibody recognizes 24 
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preferably β1,5-linked Galf-residues that are present in all forms of galactomannan (cell-wall 1 
bound, membrane bound or secreted) (42) as well as in some O-glycans (23). Moreover a second 2 
binding epitope, Galf(β1,2)Man, which is part of galactofuranosylated N-glycans has been 3 
postulated (29). Thus, EB-A2 can be used to simultaneously detect galactomannan and 4 
galactofuranosylated glycoproteins. Western blot analysis of wt and glfA* total mycelial extracts 5 
labeled with horseradish peroxidase (HRP) conjugated EB-A2 revealed a smear migrating 6 
around 40 to 80 kDa in accordance with previous findings (42). In contrast, the ∆glfA mycelial 7 
extract was not stained at all, indicating absence of Galf in the galactomannan and glycoproteins 8 
of this mutant (Fig. 2A, left). In contrast, Concanavalin A (ConA) used as loading control bound 9 
slightly better to the ∆glfA extract than to those of wt and glfA* (Fig. 2A, right). The lack of Galf 10 
in the ∆glfA mutant might increase the accessibility of the mannan for ConA and thus could 11 
explain this finding.  12 
Similarly, the absence of Galf in ∆glfA glycolipids was shown by the absence of reactivity to the 13 
monoclonal antibody MEST-1. This antibody that recognizes β1,3- and β1,6-linked Galf residues 14 
(43) labeled several A. fumigatus glycosylinositolphosphoceramides (GIPCs) after separation by 15 
high-performance thin layer chromatography as previously shown (47) but did not label 16 
glycosphingolipids extracted from the ∆glfA mutant (Fig. 2B, left). The upper bands observed in 17 
this panel might be attributed to GIPCs containing 1 or 2 Galf and 2 or 3 mannose residues as 18 
recently described (41,47). In addition, Simenel et al. reported an unusual GIPC containing a 19 
Galf residue substituted by a choline phosphate. The lower band present in the wt chromatogram 20 
could correspond to a similar GIPC. Staining of glycolipids by orcinol was used as loading 21 
control (Fig. 2B, right). The simpler ∆glfA chromatogram is compatible with the absence of Galf 22 
containing GIPCs. The uppermost band observed in the chromatogram most probably correspond 23 
to Man(α1,3)Man(α1,2)Ins-P-Cer while the band just beneath could be attributed to 24 
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Man(α1,2)Man(α1,3)Man(α1,2)Ins-P-Cer (47). The chromatograms obtained from the 1 
reconstituted mutant glfA* and wt were undistinguishable (data not shown).  2 
Additionally, N-glycans enzymatically released from A. fumigatus secreted proteins were 3 
analyzed by capillary electrophoresis after fluorescent labeling (20,8). The profiles obtained are 4 
presented in figure 3A (panels 1 and 2). The peaks labeled 1, 2, 3, 4 and 5 present in both 5 
electropherograms co-migrated with reference oligosaccharides M5 to M9 (Fig. 3A; panel 9 and 6 
Fig. 3B). Moreover, digestion of these N-glycans by Trichoderma reesei α1,2-mannosidase 7 
indicates that 2, 3, 4 and 5 arise from substitution of oligosaccharide 1 with one to four mannose 8 
residues linked in α1,2 (Fig. 3A; panels 3 and 4). The profile obtained with wt N-glycans (Fig. 9 
3A; panel 1) presents four additional peaks labeled 1a, 2a, 3a and 4a that were absent from glfA 10 
N-glycans. The retention times of these peaks suggest that they arise from substitution of 11 
oligosaccharides 1-4 with a single Galf residue. The presence of a terminal non-reducing Galf 12 
residue in A. fumigatus N-glycans has been previously reported (9) and was demonstrated by 13 
hydrofluoric acid (HF) treatment of the N-glycans after Trichoderma reesei α1,2-mannosidase 14 
digestion (Fig. 3A, panels 5 and 6). This mild acid treatment, known to release Galf, entirely 15 
converted oligosaccharide 1a into oligosaccharide 1 (Fig. 3A; panels 3 and 5). In contrast, HF 16 
treatment did not change the profile of ∆glfA N-glycans digested with α1,2 mannosidase (Fig. 17 
3A, panels 4 and 6).  18 
Interestingly, the comparison of wt and ∆glfA N-glycans digested with T. reesei α1,2 19 
mannosidase or Jack Bean mannosidase helps positioning the Galf residue. Alpha1,2-20 
mannosidase treatment converted the oligosaccharides 2a, 3a and 4a into 1a while the 21 
oligosaccharides 2, 3 and 4 generated 1 (Fig. 3A; compare panels 1 and 2 with 3 and 4). This 22 
indicates that the Galf residue does not protect any mannose residues from the exomannosidase 23 
digestion and thus does not substitute an α1,2-linked mannose (Fig. 3A; panels 3 and 4). 24 
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Moreover, Jack Bean mannosidase digestion of wt N-glycans resulted in a major peak (peak 7), 1 
attributed to GalfMan3GlcNAc2 from its retention time, in addition to Man1GlcNAc2 (peak 6) 2 
expected from digestion of high-mannose type N-glycans (Fig. 3A; panels 7 and 8). These 3 
experiments do not allow for the determination of  the detailed N-glycan structure but suggest 4 
that they resemble the N-glycans of A. niger α-glucosidase and α-galactosidase (44,45). More 5 
importantly, these experiments demonstrate the absence of Galf in the ∆glfA N-glycans. 6 
 7 
Loss of Galf
 
alters morphology and growth of A. fumigatus. The ∆glfA strain exhibited a 8 
marked growth defect on solid minimal media or complete media when compared to wt. This 9 
effect could be observed for a wide range of temperatures (Fig. 4) and was statistically different 10 
in all cases (P < 0.001, t test, n = 3). The most severe effect was found at 42 °C with a 75 % 11 
reduction in radial growth (Fig. 4C). In parallel, ∆glfA conidiation was diminished by 90 % at 37 12 
°C and was almost absent at 42 °C. In contrast, the onset and rate of germination of wt, ∆glfA 13 
and glfA* conidia were similar. In minimal media at 37 °C, the conidia of all strains started 14 
forming germ tubes at 3.2 h and reached 100 % germination within 8 to 9 h (data not shown).  15 
Scanning electron micrographs of intact mycelium, conidiophores and conidia of ∆glfA did not 16 
reveal any obvious morphologic differences. However, the observation of fractured mycelium 17 
revealed a marked reduction of the ∆glfA cell wall thickness (Fig. 5). Measurements indicated 18 
that the cell wall of wt A. fumigatus varies from 85 to 315 nm which is in good agreement with 19 
earlier findings (39). In contrast, ∆glfA cell wall thickness ranged from 85 to 150 nm. The mean 20 
values (± standard deviation) of cell wall thickness obtained from 25 measurements were 227.5 21 
nm (± 15.98 nm) and 109.7 nm (± 11.3 nm) for wt and ∆glfA hyphae respectively. The cell wall 22 
of ∆glfA was thus approximately half the thickness of the wild type cell wall. 23 
 24 
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∆glfA is more susceptible to drugs. The structural cell wall defect caused by Galf deficiency 1 
was accompanied by an increased susceptibility to several antifungal agents (Table 2). MICs 2 
determined in a broth microdilution test were slightly reduced for amphotericin B and 3 
caspofungin in the ∆glfA mutant. A more pronounced increase in susceptibility was seen for 4 
voriconazole (0.04 mg/L for ∆glfA compared to 0.3 mg/L for wt) and nikkomycin Z (63-125 5 
mg/L for ∆glfA and 500 mg/mL for wt), suggesting an increased permeability of the cell wall 6 
caused by the loss of Galf. In contrast, the sensitivity towards oxidative stress remained 7 
unchanged as indicated by equal MICs for H2O2 in both wt and ∆glfA. 8 
 9 
∆glfA displays attenuated virulence in a murine model of invasive aspergillosis. The 10 
influence of the glfA deletion on pathogenicity of A. fumigatus was assessed in a low-dose 11 
infection model of invasive aspergillosis (25). Cyclophosphamide was used to induce 12 
neutropenia in female Balb/c mice and a single dose of cortisone acetate was administered before 13 
intranasal infection with 20,000 A. fumigatus conidia. Neutropenia was maintained throughout 14 
the observation period of 13 days and survival was recorded daily (Fig. 6A). 90 % of the animals 15 
infected with wt did not survive day seven after infection, whereas half of the mice infected with 16 
∆glfA were still alive on day 13. A logrank test on wt and ∆glfA survival data confirmed that the 17 
observed difference was statistically significant (P = 0.0004). The attenuation in virulence could 18 
clearly be attributed to the absence of glfA, since animals infected with the reconstituted wild 19 
type strain glfA* showed a survival pattern nearly identical to wt (no significant difference in 20 
logrank test, P = 0.559). Histological examination of lung tissue from mice infected with wt, 21 
∆glfA and glfA* 5 days after inoculation showed evident fungal growth surrounding bronchioles 22 
and tissue penetration (Fig. 7). For each strain, inflammatory cells were rarely observed at the 23 
sites of infection.  24 
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To correlate the delay in the onset and progression of mortality with a growth defect, fungal 1 
burden in lungs of infected mice was determined by quantitative PCR (Fig. 6B). Mice were 2 
treated and infected as described above. After two, four and six days, animals were sacrificed 3 
and their lungs taken. DNA was isolated from homogenized lung tissue and fungal content 4 
determined by amplification of a part of A. fumigatus ribosomal DNA. As shown in figure 6B, 5 
growth of ∆glfA was restricted in vivo when compared to wt, which was in agreement with the 6 
slower growth observed in vitro. 7 
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DISCUSSION 1 
The essential role of the β1,3-glucan in cell wall organization and growth of several pathogenic 2 
fungi has been the basis for the development of the echinocandins (11). Likewise, inhibitors of 3 
chitin biosynthesis are currently explored as new antifungal drugs since chitin is an important 4 
structural element of the fungal cell wall (6). In contrast, although it is a major component of the 5 
cell wall and extracellular matrix, the role of galactomannan had not yet been investigated since 6 
the enzymes involved in its biosynthesis are unknown. Recently, we and others characterized the 7 
UDP-galactopyranose mutase (UGM) of various pathogenic eukaryotes including  A. fumigatus 8 
(2,5). In prokaryotes, like in the protozoan Leishmania, this enzyme is the only route to the 9 
formation of UDP-Galf, the donor substrate of galactofuranosyltransferases, and thus controls the 10 
biosynthesis of all Galf containing molecules. Likewise, A. fumigatus UGM was found to be 11 
essential for the biosynthesis of galactomannan as well as some glycosphingolipids and 12 
glycoproteins. Like in other organisms (16,32), deletion of the glfA gene resulted in the complete 13 
absence of Galf, as shown for instance by the absence of reactivity to the antibody EB-A2.  14 
Besides demonstrating the lack of Galf in the ∆glfA mutant, our analyses provide useful 15 
structural information of A. fumigatus N-glycans. Treatment of wild type secreted proteins with 16 
PNGase F released galactofuranosylated high-mannose type N-glycans. The size of the 17 
oligosaccharides and presence of a single Galf residue is in agreement with previous studies in 18 
filamentous fungi (26,29). Moreover, analysis of these oligosaccharides after digestion by Jack 19 
bean- or T. reesei α1,2-mannosidase helps positioning the Galf residue. These data and the 20 
comparison with high-mannose standards suggest that the N-glycans from A. fumigatus secreted 21 
proteins resemble those of A. niger α-D-galactosidase and α-D-glucosidase (45,44,49). These N-22 
glycans might have simply arisen from trimming of the Glc3Man9GlcNAc2 precursor and 23 
substitution by a Galf
 
residue. Aspergilli indeed contain several α1,2-mannosidase genes and 24 
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trimming of high mannose glycans has been shown previously (52,13). Interestingly, Galf 1 
addition has been suggested to act as a stop signal for mannose addition in analogy to the role 2 
proposed for α1,3-linked terminal mannose in Saccharyomyces cerevisiae (29,49). However, 3 
preventing the addition of galactofuranose does not result in an increased size of the 4 
oligosaccharides. On the contrary, Man5GlcNAc2 is the main oligosaccharide found in the ∆glfA 5 
mutant while GalfMan6GlcNAc2 is predominant in wild type. 6 
Although glfA deletion has been shown to be lethal in Mycobacterium smegmatis (32), the in 7 
vitro viability of A. fumigatus ∆glfA mutant is unsurprising since Galf occupies a non-reducing 8 
terminal position in the molecules of this fungus. Hence, the absence of Galf does not perturb the 9 
basic organization of the cell wall, as would the absence of the underlying structures. 10 
Nevertheless, it resulted in marked alterations of the cell surface and notably a thinner cell wall 11 
as revealed by electron microscopy. The basis of this drastic change is unclear and difficult to 12 
attribute to a particular cell wall component since GPI-/cell wall bound galactomannan, N-13 
glycans, O-glycans and GIPCs are affected by Galf deficiency. In other fungi, the loss of 14 
terminal sugar residues has sometimes been associated with reduced cell wall strength. For 15 
instance, a Schizosaccharomyces pombe mutant deficient in cell wall galactosylation displays 16 
morphological changes, attenuated growth and a 25-35 % reduction in cell wall thickness (46).  17 
The structural changes originating from the glfA deletion are associated with slower growth 18 
indicating that Galf plays an important role in A. fumigatus morphogenesis. The temperature-19 
sensitive growth defect at higher temperature displayed by the ∆glfA mutant is reminiscent to 20 
that observed in the ∆AfPmt1 mutant, a mutant characterized by reduced O-glycosylation (53). 21 
Interestingly, an influence of Galf deficiency on the growth rate was also observed in ∆glfA 22 
mutants of Aspergillus nidulans and Aspergillus niger (10). Conversely glfA deletion had no 23 
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effect on the in vitro growth of Leishmania parasites (16) highlighting that the role of Galf 1 
cannot be translated to every Galf containing organism. 2 
The ability to thrive at 37 °C is a characteristic of human pathogens that has been shown to 3 
correlate with virulence potential in the case of A. fumigatus (31). Consequently, mutations that 4 
affect the growth of fungi at mammalian body temperature are commonly associated with 5 
attenuated virulence (40). In this study, we observed slower growth of the A. fumigatus ∆glfA 6 
mutant in vitro but also in vivo using quantitative PCR. In agreement with this observation, the 7 
mutant was clearly attenuated in virulence showing a delay in both the onset and progression of 8 
mortality when tested in a low dose mouse infection model of invasive aspergillosis. An altered 9 
immune response caused by the different cell wall structure of the ∆glfA mutant may also 10 
contribute to the attenuation in virulence. However, no differences in adherence and uptake of wt 11 
and ∆glfA conidia by murine bone-marrow derived dendritic cells or in the production of TNF-α 12 
or IL-10 by infected murine bone-marrow derived macrophages were observed (K. Kotz, F. Ebel 13 
and F.H. Routier, unpublished data).  14 
The value of echinocandins in invasive aspergillosis treatment resides in their synergistic effects 15 
with azoles and amphotericin B. Similarly, chitin synthesis inhibitors demonstrate synergy with 16 
echinocandins and azoles (24). These synergistic effects that offer new options for combination 17 
antifungal therapy are most likely due to greater cell wall permeability. We did note an increase 18 
in susceptibility of the ∆glfA mutant to several antifungal agents, notably to voriconazole. 19 
However, in the liquid culture conditions classically used for antifungal susceptibility testing, the 20 
fungus is not surrounded by extracellular matrix. This extracellular matrix that delays the 21 
penetration of drug is rich in galactomannan (3) and is probably altered in the ∆glfA mutant as 22 
suggested by the compact appearance of colonies on agar plates. In vivo a greater increase in 23 
susceptibility of the ∆glfA mutant to drugs would therefore be expected. Besides the attenuated 24 
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virulence, this suggests that inhibitors of UGM might be useful in antifungal therapy. The 1 
absence of Galf
 
biosynthesis in mammals would represent a considerable advantage for the 2 
development of antifungal drugs with selective toxicity.  3 
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FIGURE LEGENDS 1 
Figure 1 A) Schematic representation of the chromosomal glfA locus in wild type, ∆glfA and 2 
reconstituted wild type glfA*. Thick black bars show flanking regions used for homologous 3 
recombination. The positions of probes (1-3) used for Southern Blot along with respective 4 
restriction fragments (size in kb) are indicated. B) Southern Blots of genomic DNA digested with 5 
indicated restriction enzymes and hybridised to different digoxigenin-labeled probes. wt, wild 6 
type; ble/tk, phleomycin resistance/thymidine kinase fusion gene; P, promoter; T, terminator.  7 
 8 
Figure 2 A) Western Blots of A. fumigatus mycelial extracts containing glycoproteins and cell 9 
wall polysaccharides stained with horseradish peroxidase conjugates of either Galf-specific mAb 10 
EB-A2 (left) or α-mannose binding lectin Concanavalin A (right). B) A. fumigatus GIPCs 11 
separated by High Performance Thin Layer Chromatography and stained with Galf-specific mAb 12 
MEST-1 (left) or orcinol (right). White bars indicate the origin. 13 
 14 
Figure 3 A) Electropherograms of fluorescently labeled N-glycans enzymatically released from 15 
secreted A. fumigatus glycoproteins. Oligosaccharides from wt and ∆glfA were either untreated 16 
(panels 1 and 2), digested with T. reesei α1,2-exomannosidase with or without hydrofluoric acid 17 
treatment (panels 3 to 6) or digested with Jack Bean α-mannosidase (panels 7 and 8). Bovine 18 
RNAse B N-glycans served as reference (panel 9). B) Structures of bovine RNAse B reference 19 
N-glycans. C) Major N-glycans found on A. niger α-galactosidase and α-glucosidase (44,45). 20 
Black squares, N-acetylglucosamine; grey circles, mannose; white pentagon, galactofuranose.  21 
 22 
Figure 4 A) Colony morphology of A. fumigatus on minimal agar after two days. White bars 23 
represent 1 cm. B) Absolute and relative (compared to wild type) growth rates derived from three 24 
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independent experiments. P value from a t test indicates statistical significance (***, P < 0.001; 1 
ns, not significant). 2 
 3 
Figure 5 Field emission scanning electron micrographs of cross-fractured mycelial walls of A. 4 
fumigatus wt and ∆glfA. Panel 1 and 3 display the highest measurement of cell wall thickness. 5 
Panel 2 and 4 present two measurements illustrating the 50% reduction of ∆glfA cell wall 6 
thickness. 7 
 8 
Figure 6 A) Survival of immunosuppressed mice infected intranasally with A. fumigatus wt 9 
(continuous), ∆glfA (dotted) or glfA* (dashed) and uninfected mice (dot-dashed). Each group 10 
consisted of 20 animals. B) Quantitative PCR determination of A. fumigatus burden (measured as 11 
conidial equivalents, see Material and Methods) in lung tissue from immunosuppressed mice 12 
infected with wt (continuous) or ∆glfA (dotted). Each datapoint represents mean values obtained 13 
from three to five animals. Error bars indicate standard error of the mean. 14 
 15 
Figure 7 Periodic Acid Schiff stained lung sections of mice infected with A. fumigatus wild type 16 
(left), ∆glfA (middle) or glfA* (right). Fungal colonies appear purple/red. Infected sites are 17 
typically surrounded by areas of necrotic tissue but show no or hardly any infiltrating leukocytes. 18 
The scale bar represents 100 µm.19 
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TABLES 1 
Table 1. DNA oligonucleotides used in this study. 2 
Oligonucleotide  Sequence (5’->3’; restriction site underlined) Description (Restriction site) 
PS1 ATAAGCGGCCGCAAGCTGGGAACGCGATTCAA 5’ flanking region p∆glfA reverse (NotI) 
PS12 TATACCGCGGCTGCCAAGCTATCAGTTTCC 5’ flanking region p∆glfA sense (SacII) 
PS3 ATCCGGTGCTCAGGTATTCGCCA 3’ flanking region p∆glfA sense (EcoRV) 
PS4 ATCCATCGATCATATCCTATGCGGTCTCAG 3’ flanking region p∆glfA reverse (ClaI) 
PS66A TTACGCATTCCCAGCAGTTG Southern Blot probe 1 sense 
PS67A TGCGCTGTGATGAATGGTGT Southern Blot probe 1 reverse 
PS68A TCCACAATACGTCCCCTACA Southern Blot probe 2 sense 
PS69A GTATGAACCCTCTCCCAATG Southern Blot probe 2 reverse 
PS20 AAGGTCGTTGCGTCAGTCCA Southern Blot probe 3 sense 
PS21 TCGATGTGTCTGTCCTCC Southern Blot probe 3 reverse 
PS23s ATGCCGCTCTCGAGGCTCGT Site-directed mutagenesis glfA* sense 
(XhoI) 
PS23r CACGAGCCTCGAGAGCGGCA Site-directed mutagenesis glfA* reverse 
(XhoI) 
PS28 ATATGCGGCCGCAAACAGGAGCGAAGTAGT 5’ flanking region pglfA* sense (NotI) 
PS31 ATATCCCGGGAGTTTGGTGCTGTGGTAGGT 3’ flanking region pglfA* reverse (XmaI) 
PS78 CGTGTCTATCGTACCTTGTTGCTT 18S rRNA gene fragment sense 
PS79 AACTCAGACTGCATACTTTCAGAACAG 18S rRNA gene fragment reverse 
probe FAM-CCCGCCGAAGACCCCAACATG-TAMRAa qPCR hybridisation probe 
aFAM, carboxyfluorescein; TAMRA, carboxytetramethylrhodamine. 3 
 4 
Table 2. MICs of various antifungal agents against A. fumigatus mutants obtained from a broth 5 
microdilution assay. 6 
AmBa Vorb Casc NiZd H2O2e Genotype 
mg/L 
wt 3.9 0.3 62.5 500 218 
∆glfA 2.0 0.04 31.3 62.5-125 218 
glfA* 3.9 0.3 62.5 500 218 
aAmphotericin B (MIC90), bVoriconazole (MIC50), 7 
cCaspofungin (MIC90), dNikkomycin Z (MIC50), 8 
eMIC100.  9 
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